Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
April 12 2024 - 4:22PM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that
the conference call to discuss new clinical efficacy and safety
data from the Phase 1/2 study of GTX-102 for the treatment of
Angelman syndrome that will be presented at the American Academy of
Neurology Meeting (AAN), will now be taking place on Monday, April
15, 2024 at 8 a.m. Eastern Time (ET). The slides accompanying the
call will be shared on company’s website at
https://ir.ultragenyx.com/events-presentations before the call.
Conference Call and Webcast Information
The live and replayed webcast of the call will be available
through the company’s website at
https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing
novel products to patients for the treatment of serious rare and
ultrarare genetic diseases. The company has built a diverse
portfolio of approved therapies and product candidates aimed at
addressing diseases with high unmet medical need and clear biology
for treatment, for which there are typically no approved therapies
treating the underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at: www.ultragenyx.com.
Contacts
Ultragenyx Pharmaceutical Inc.
Investors
Joshua Higa
+1-415-475-6370
ir@ultragenyx.com
Media
Carolyn Wang
+1-415-225-5050
media@ultragenyx.com
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Apr 2024 to May 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From May 2023 to May 2024